Search

Your search keyword '"Seagen Inc. -- Licensing agreements"' showing total 24 results
Start Over Descriptor "Seagen Inc. -- Licensing agreements" Topic news, opinion and commentary
24 results on '"Seagen Inc. -- Licensing agreements"'

1. Seagen, Lava Therapeutics enter worldwide license agreement for LAVA-1223

Subjects
Seagen Inc. -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

Seagen Inc. (SGEN) and LAVA Therapeutics N.V. (LVTX) announced an exclusive license agreement in which Seagen will work to develop, manufacture and commercialize LAVA-1223. LAVA-1223 is an advanced preclinical asset [...]

Published
2022

2. Seagen and Zai Lab Announce Regional Strategic Collaboration and License Agreement for TIVDAK(r) (tisotumab vedotin-tftv)

Subjects
Zai Lab Ltd. -- Licensing agreements, Seagen Inc. -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Cervical cancer, Chemotherapy, Cancer -- Chemotherapy, Pharmaceutical industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

BOTHELL: SEAGEN INC. has issued the following news release: Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and Zai Lab Limited (Nasdaq: ZLAB; HKEX: [...]

Published
2022

3. Seagen and LAVA Therapeutics Announce Exclusive Worldwide License Agreement to Advance LAVA-1223, a Preclinical Gamma Delta Bispecific T Cell Engager for EGFR-Expressing Solid Tumors

Subjects
Seagen Inc. -- Licensing agreements, Tumors, T cells, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

PHILADELPHIA: LAVA Therapeutics N.V.; Seagen Inc. has issued the following news release: Seagen Inc. (Nasdaq: SGEN), a world leader and pioneer in antibody-drug conjugate (ADC) therapies, and LAVA Therapeutics N.V. [...]

Published
2022

4. Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs

Subjects
Five Prime Therapeutics Inc. -- Licensing agreements, Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biopharmaceutics -- Licensing agreements, Biotechnology industry -- Licensing agreements, Monoclonal antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

SOUTH SAN FRANCISCO: Five Prime Therapeutics, Inc. has issued the following press release: Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision [...]

Published
2020

5. News Flash:Five Prime Therapeutics Licenses Antibodies to Seattle Genetics for Use in Novel Antibody Drug Conjugate (ADC) Programs

Subjects
Five Prime Therapeutics Inc. -- Licensing agreements, Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biopharmaceutics -- Licensing agreements, Biotechnology industry -- Licensing agreements, Monoclonal antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Five Prime Therapeutics, Inc. (NASDAQ: FPRX), a clinical-stage biotechnology company focused on developing immune modulators and precision therapies for solid tumor cancers, today announced a global license agreement with Seattle [...]

Published
2020

6. Seattle Genetics and BeiGene Announce Global License Agreement for Advanced Preclinical Product Candidate

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

BOTHELL: Seattle Genetics, Inc. and BeiGene has issued the following press release: Seattle Genetics, Inc. (Nasdaq: SGEN) and BeiGene, Ltd. (Nasdaq: BGNE; HKEX: 06160) today announced that the companies have [...]

Published
2019

7. PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

MADRID: PharmaMar has issued the following news release: PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which [...]

Published
2018

8. Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cancer -- Care and treatment, Proteins, Antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(r) technology platform for cancer, [...]

Published
2018

9. PharmaMar Licenses Fully Synthetic Marine-derived Payloads to Seattle Genetics for Use in Drug Conjugates

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, Business, News, opinion and commentary
Abstract

MADRID, February 14, 2018 /PRNewswire/ -- PharmaMar (MCE: PHM) has announced today the signing of an exclusive licensing agreement with Seattle Genetics Inc. (SGEN: NASDAQ GS) under which Seattle Genetics [...]

Published
2018

10. Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cancer -- Care and treatment, Proteins, Antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Germany: Pieris Pharmaceuticals, Inc. has issued the following press release: Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(r) technology platform for cancer, [...]

Published
2018

11. Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cancer -- Care and treatment, Proteins, Antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(r) technology platform for cancer, [...]

Published
2018

12. Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cancer -- Care and treatment, Proteins, Antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(r) technology platform for cancer, [...]

Published
2018

13. Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cancer -- Care and treatment, Proteins, Antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Germany: Pieris Pharmaceuticals, Inc. has issued the following press release: Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(r) technology platform for cancer, [...]

Published
2018

14. Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cancer -- Care and treatment, Proteins, Antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(r) technology platform for cancer, [...]

Published
2018

15. Pieris Pharmaceuticals and Seattle Genetics Announce Multi-Program Immuno-Oncology Collaboration

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cancer -- Care and treatment, Proteins, Antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Germany: Pieris Pharmaceuticals, Inc. has issued the following press release: Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(r) technology platform for cancer, [...]

Published
2018

16. Seattle Genetics and Pieris Pharmaceuticals Announce Multi-Program Immuno-Oncology Collaboration

Subjects
Seagen Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biotechnology industry -- Licensing agreements, Viral antibodies, Cancer -- Care and treatment, Proteins, Antibodies, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Pieris Pharmaceuticals, Inc. (NASDAQ: PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin(r) technology platform for cancer, [...]

Published
2018

17. Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132)

Subjects
Seagen Inc. -- Licensing agreements, Immunomedics Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement [...]

Published
2017

18. Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132)

Subjects
Seagen Inc. -- Licensing agreements, Immunomedics Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: - Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license [...]

Published
2017

19. Seattle Genetics Terminates License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132)

Subjects
Seagen Inc. -- Licensing agreements, Immunomedics Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced that it has agreed to terminate its license agreement [...]

Published
2017

20. Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors

Subjects
Seagen Inc. -- Licensing agreements, Immunomedics Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Tumors, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: [...]

Published
2017

21. Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors

Subjects
Seagen Inc. -- Licensing agreements, Immunomedics Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Tumors, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: [...]

Published
2017

22. Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors

Subjects
Seagen Inc. -- Licensing agreements, Immunomedics Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Tumors, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: [...]

Published
2017

23. Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors

Subjects
Seagen Inc. -- Licensing agreements, Immunomedics Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Tumors, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: [...]

Published
2017

24. Seattle Genetics Announces Global License Agreement with Immunomedics for Sacituzumab Govitecan (IMMU-132), a Promising Late-Stage ADC for Solid Tumors

Subjects
Seagen Inc. -- Licensing agreements, Immunomedics Inc. -- Licensing agreements, Biological products industry -- Licensing agreements, Tumors, Biological products -- Licensing agreements, Biotechnology industry -- Licensing agreements, Company licensing agreement, General interest, News, opinion and commentary
Abstract

Bothell: Seattle Genetics, Inc. has issued the following press release: Seattle Genetics, Inc. (Nasdaq: SGEN), a global biotechnology company, today announced a development and license agreement with Immunomedics, Inc. (Nasdaq: [...]

Published
2017

Catalog

Books, media, physical & digital resources
See catalog results